CGI-1842

DB12744InvestigationalSmall molecule

JI-101 has been used in trials studying the treatment of Cancer, Colon Cancer, Neuroendocrine, Ovarian Cancer, and Advanced Solid Tumors.

Mechanism: Pharmacologically active on Platelet-derived growth factor receptor beta, Vascular endothelial growth factor receptor 2, and Ephrin type-B receptor 4
Curator reviewed
Formula / weight: C₂₂H₂₀BrN₅O₂ · 466.339 g/mol (avg)
Code names: JI-101

Resolves to

Compound

Structure

InChIKeyZXBFYBLSJMEBEP-UHFFFAOYSA-NSMILESCOC1=CC=C(Br)C=C1NC(=O)NC1=C2C=CN(CC3=CC=NC(N)=C3)C2=CC=C1

Targets

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with CGI-1842, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.